Cargando…

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene

INTRODUCTION: PARP inhibition may enhance antitumor responses in BAP1-associated mesothelioma by inducing synthetic lethality. METHODS: A single-center, nonrandomized, phase 2 trial was conducted, in which patients with refractory mesothelioma were given olaparib 300 mg twice daily in a 21-day cycle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghafoor, Azam, Mian, Idrees, Wagner, Cathy, Mallory, Yvonne, Agra, Maria Garcia, Morrow, Betsy, Wei, Jun S., Khan, Javed, Thomas, Anish, Sengupta, Manjistha, Steinberg, Seth M., Hassan, Raffit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502774/ https://www.ncbi.nlm.nih.gov/pubmed/34661178 http://dx.doi.org/10.1016/j.jtocrr.2021.100231

Ejemplares similares

Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma
por: Nair, Nishanth Ulhas, et al.
Publicado: (2023)

Germline BAP1 mutations predispose to malignant mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2011)

Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma
por: Kalra, Neetu, et al.
Publicado: (2015)

BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma
por: Alakus, Hakan, et al.
Publicado: (2015)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Bilateral Pleural Mesothelioma In Situ and Peritoneal Mesothelioma In Situ Associated With BAP1 Germline Mutation: A Case Report
por: MacLean, Alyssa, et al.
Publicado: (2022)

Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members
por: Kittaneh, Muaiad, et al.
Publicado: (2018)

Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma
por: Ewens, K. G., et al.
Publicado: (2018)

Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma
por: Bononi, Angela, et al.
Publicado: (2020)

Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer
por: Tesch, Megan E., et al.
Publicado: (2020)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Germline mutations in BAP1 predispose to melanocytic tumors
por: Wiesner, Thomas, et al.
Publicado: (2011)

Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
por: Pulford, Emily, et al.
Publicado: (2017)

Germline BAP1 mutations induce a Warburg effect
por: Bononi, Angela, et al.
Publicado: (2017)

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
por: Ladanyi, Marc, et al.
Publicado: (2019)

A population-based analysis of germline BAP1 mutations in melanoma
por: O’Shea, Sally J., et al.
Publicado: (2017)

Functional characterisation guides classification of novel BAP1 germline variants
por: Hong, Jing Han, et al.
Publicado: (2020)

BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
por: Carbone, Michele, et al.
Publicado: (2012)

BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
por: Guazzelli, Alice, et al.
Publicado: (2019)

The Rarest of the Rare: A Case of BAP1-Mutated Primary Peritoneal Mesothelioma
por: Gupta, Aanchal, et al.
Publicado: (2021)

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
por: Pandey, Gaurav Kumar, et al.
Publicado: (2023)

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
por: Shrestha, Raunak, et al.
Publicado: (2019)

BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma
por: Ishii, Yuki, et al.
Publicado: (2021)

Case report: Mesothelioma and BAP1 tumor predisposition syndrome: Implications for public health
por: Vimercati, Luigi, et al.
Publicado: (2022)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

To BaP or not to BaP? That is the question.
por: Goldstein, L S
Publicado: (2001)

Genes versus Environment: cytoplasmic BAP1 determines the toxic response to environmental stressors in mesothelioma
por: Amelio, Ivano
Publicado: (2017)

A case of slowly progressive malignant pericardial mesothelioma suggesting the involvement of BAP1 loss
por: Fukasawa, Naoto, et al.
Publicado: (2022)

Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma
por: Zuccatosta, Lina, et al.
Publicado: (2023)

Commentary: Case report: Mesothelioma and BAP1 tumor predisposition syndrome: implications for public health
por: Sassorossi, Carolina, et al.
Publicado: (2023)

Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma
por: Carbone, Michele, et al.
Publicado: (2023)

CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma
por: Karnan, Sivasundaram, et al.
Publicado: (2023)

Clinical and Molecular Validation of BAP1, MTAP, P53, and Merlin Immunohistochemistry in Diagnosis of Pleural Mesothelioma
por: Chapel, David B., et al.
Publicado: (2022)

BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
por: Barnett, Sarah E., et al.
Publicado: (2023)

BAP1 Malignant Pleural Mesothelioma Mutations in Caenorhabditis elegans Reveal Synthetic Lethality between ubh-4/BAP1 and the Proteasome Subunit rpn-9/PSMD13
por: Martínez-Fernández, Carmen, et al.
Publicado: (2023)

Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant
por: Kuemmel, Sherko, et al.
Publicado: (2020)

Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
por: Mukherjee, Shibani, et al.
Publicado: (2020)

Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology
por: Andrici, Juliana, et al.
Publicado: (2015)

Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
por: Kushitani, Kei, et al.
Publicado: (2018)

Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic Response
por: Osmanbeyoglu, Hatice Ulku, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p3em3rkdpelfm6m6moa5v0s18s